The Pharmacy Times® Chronic Kidney Disease Resource Center is a comprehensive resource for clinical news and expert insights on issues related to long-term disease of the kidneys leading to renal failure.
April 24th 2024
Iptocopan demonstrated superiority when treating patients with immunoglobulin A nephropathy and is the first drug to specifically target the alternative complement pathway.
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Advances in the Treatment of Metastatic Renal Cell Carcinoma: New Horizons in Targeted Therapies
1.0 Credit / Genitourinary Cancer, Oncology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
IVIG-Based Treatment Increased Survival Rates of Renal Transplantation, Stabilizing Graft Function
August 2nd 2023With an intravenous immunoglobulin-based treatment protocol, individuals who underwent renal transplantation and who were presensitized achieved intermediate-term graft and recipient survival results at 98%.
Read More
Guidelines Recommend SGLT2 Inhibitors for Nearly All Patients With Heart Failure, Kidney Disease
March 6th 2023The 2022 American Heart Association, American College of Cardiology, and Heart Failure Society of America guidelines recommend SGLT2 inhibitors for nearly all patients in cardiovascular practice.
Read More
Newer Cardiovascular Drugs Are Being Incorporated Into Practice, but Access Remains a Challenge
March 6th 2023Pharmacists play a vital role in ensuring that patients can afford their medications, either by advising them on more affordable options or working with insurers and prescribers to find cheaper alternatives.
Read More
Study Finds RAS Inhibition Has Little Effect on Outcomes in Advanced Chronic Kidney Disease
December 16th 2022A randomized study of renin-angiotensin system inhibitors in advanced chronic kidney disease found that patients who continued receiving therapy had similar outcomes to those who discontinued treatment.
Read More